Recent Lessons

Show all results for ""

Feature Overview

Ace your exams with our all-in-one platform for creating and sharing quizzes and tests.

Quizzes

Create quizzes and tests automatically from your content using AI.

Flashcards

Automatically turn your notes into digital flashcards.

Share, Export & Embed

Share with classmates or export to Excel and your learning management system.

Stats & Reporting

Auto-grading quizzes and tests with detailed stats and reports.

Mobile Apps

The smarter way to study – wherever you are.

Pricing

Search...

3 Questions

0 Views

Trastuzumab and Heart Health

Choose a study mode

Play Quiz

Study Flashcards

Spaced Repetition

Chat to lesson

Podcast

Play an AI-generated podcast conversation about this lesson

Questions and Answers

What is the recommended action if a patient receiving trastuzumab therapy experiences a decrease in LVEF?

Increase trastuzumab dosage

Continue trastuzumab therapy

Withhold trastuzumab therapy and reassess LVEF after four weeks (correct)

Discontinue trastuzumab therapy immediately

Which of the following factors increases the risk of trastuzumab cardiotoxicity?

Male gender

Underweight

Previous or concurrent use of taxanes (correct)

Young age

What is the recommended treatment for trastuzumab-induced heart failure?

No treatment is necessary

Standard heart failure medication (correct)

Antibiotics

Surgery

Study Notes

Trastuzumab cardiotoxicity can cause a decrease in LVEF and clinical heart failure.
Symptoms of heart failure have been reported in 3-7% of patients receiving trastuzumab.
Age, previous or concurrent anthracycline use, and obesity are risk factors for trastuzumab cardiotoxicity.
Cardiac function monitoring is recommended for patients receiving anthracyclines and trastuzumab.
Patients should be counseled on reducing cardiovascular risk through lifestyle changes.
Standard heart failure medication is recommended for trastuzumab-induced heart failure.
Trastuzumab therapy should be withheld and LVEF reassessed after four weeks.
If LVEF remains low, trastuzumab should be discontinued.
Prophylactic use of beta blockers or ACEi/ARB may be beneficial for high-risk patients.
Cardiac biopsy specimens do not show significant myocyte destruction.

Studying That Suits You

Use AI to generate personalized quizzes and flashcards to suit your learning preferences.

Description

Test your knowledge on trastuzumab and its potential cardiotoxicity with this informative quiz. Explore the incidence, risk factors, and management of trastuzumab-induced heart failure. Learn about the importance of cardiac function monitoring, lifestyle changes, and standard heart failure medication. Discover the benefits and limitations of prophylactic use of beta blockers or ACEi/ARB in high-risk patients. Take this quiz to enhance your understanding of trastuzumab cardiotoxicity and its implications for